Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering Pharma AF drug meets primary target in trial

Bayer Schering Pharma AF drug meets primary target in trial

3rd November 2010

Bayer Schering Pharma's atrial fibrillation (AF) therapy rivaroxaban has achieved its primary endpoint in a comparative phase III clinical study.

The pharmaceutical company has announced preliminary results from the Rocket AF study, which trialled the once-daily drug against warfarin among patients with non-valvular AF at risk of stroke and non-CNS systemic embolism.

Results from the trial showed that rivaroxaban was able to deliver a comparable performance to the control treatment in terms of key safety and efficacy measures.

It means the drug met its key targets in the study, which involved around 14,000 patients enrolled in more than 1,100 centres in 45 different countries worldwide.

In-depth analysis of results will be presented by Bayer Schering Pharma at the scientific sessions of the American Heart Association later this month.

Last month, the company published new study data for its multiple sclerosis treatment Betaferon, which highlighted the long-term effectiveness of the treatment over 21 years.ADNFCR-8000103-ID-800213264-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.